We are proud of the clinical evidence, R&D achievements, and our five-year-long company development as Bluestar Genomics. Now, as a commercial-stage company, ClearNote Health continues to drive innovation in non-invasive cancer detection, with patient needs at the core of everything we pursue.

As a follow-up to FDA’s breakthrough device designation for our pancreatic cancer test panel, ClearNote Health is currently conducting two large clinical studies at multiple sites across the United States. Learn more about study design, patient criteria, and enrollment:

• Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients
• New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)